Andembry® (garadacimab-gxii) – New orphan drug approval
June 16, 2025 - CSL announced the FDA approval of Andembry (garadacimab-gxii), for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 12 years and older.
Download PDF
